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ABSTRACT
Treatment of rectal cancer has been vastly improved by advances in surgery 
and radiochemotherapy but remains an important cause of morbidity and mortality 
worldwide. A particular problem is the lack of predictive markers that can help to 
individualize treatment. The growth- and apoptosis-regulating signaling molecules 
ERK 1 and 2 are important to cancer growth and progression. They are activated 
through phosphorylation, which is initiated by a cascade involving the EGF receptor 
and RAS as upstream regulators. Moreover, in vitro studies indicate that phospho-
ERKs interfere with 5-fluorouracil-based chemotherapy. Recently, we showed that high 
levels of phospho-ERKs in rectal cancer cells predict poor responses to neoadjuvant 
(preoperative) radiochemotherapy. We now report that preoperative phospho-ERK 
levels also can subdivide high-risk rectal cancer patients into a favorable and a poor 
prognostic group with respect to recurrence-free survival. Importantly, phospho-
ERK levels were of predictive significance only in high-risk patients, who received 
adjuvant (postoperative) chemotherapy, but not in high-risk patients not receiving such 
therapy. Our results suggest that high cancer cell levels of phospho-ERK predict poor 
responsiveness to both preoperative and postoperative chemotherapy of rectal cancer.
INTRODUCTION
Treatment of rectal cancer has been substantially 
improved by the introduction of total mesorectal 
excision surgery but the disease is still associated with 
considerable morbidity and mortality. Patients with locally 
advanced rectal adenocarcinomas (LARC) are commonly 
offered neoadjuvant treatment with radiochemotherapy 
(RCT) prior to surgery [1–4]. After surgery, adjuvant 
chemotherapy may be administered to high-risk patients. 
However, it has been questioned whether all such patients 
benefit from adjuvant therapy and there is a paucity of 
reliable markers to predict the response [5].
ERK 1 and 2 (extracellular signal-regulated kinases 
1 and 2, also known as mitogen activated protein kinases: 
MAPK p44 and p42) regulate cell division, apoptosis and 
motility [6, 7]. Although encoded for by different genes, 
they subserve identical, redundant functions. ERKs are 
activated by an array of upstream regulators, including 
the EGF receptor (EGFR), RAS, and RAF. Activating 
mutations in genes encoding these regulators are central 
to the development and/or progression of colorectal and 
other cancers [8–10]. ERK activation proceeds through 
a cascade that is initiated by binding of EGF (or other 
growth factors) to cell surface receptors. Receptor binding 
initiates conversion of RAS to its active, GTP-bound form. 
Activated RAS starts a chain of events culminating in the 
activation of RAF, which, in turn, activates the MAPK/
ERK kinases (MEK) 1 and 2. MEKs activate ERKs by 
dual phosphorylation to phospho-ERKs. Most phospho-
ERKs translocate to the nucleus, where they stimulate 
transcription of genes regulating cell cycle progression 
and apoptosis [6, 7, 10–12]. MAPK phosphatases (MKPs, 
also referred to as dual specificity phosphatases; DUSPs) 
remove the activating phosphorylations on both threonines 
and tyrosines in phospho-ERKs and, thus, terminate their 
activity. Of ERK-targeting MKPs, class I enzymes (MKP-
1/DUSP1, DUSP2/PAC-1, MKP-2/DUSP 4 and DUSP5) 
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are nuclear and class II enzymes (MKP-3/DUSP6, 
MKP-X/DUSP7 and MKP-4/DUSP9) are cytoplasmic. 
MKP-1 expression is stimulated by pERKs, which, hence, 
participate in a negative feedback loop. The expression of 
such phosphatases has been linked to cancer progression 
and therapy responses [7]. Thus, steady-state levels 
of phospho-ERKs are dictated by both activating and 
inactivating regulators.
In vitro studies have demonstrated that MEK 
inhibitors (which abolish ERK phosphorylation) sensitize 
cultured cancer cells to 5-fluorouracil (5FU) as well as 
to radiation [13–15]. Using diagnostic (pre-treatment) 
biopsies, we have previously demonstrated that high 
phospho-ERK levels in rectal cancer cells are associated 
with poor RCT responses in terms of tumor regression and 
downstaging [10]. We now report that high cancer cell 
levels of phospho-ERK also subdivide high-risk patients 
into a favourable and less favourable group with respect 
to recurrence-free survival (RFS). This effect is highly 
significant for high-risk patients receiving postoperative 
chemotherapy, but not for high-risk patients, who do 
not receive such therapy. These results suggest that high 
phospho-ERK levels in cancer cell predict poor responses 
both to neoadjuvant and adjuvant chemotherapy.
RESULTS
Pre-treatment biopsies stained for phospho-ERK 
showed variable degrees of reactivity in cancer cells as 
well as in stromal and inflammatory cells (Figure 1A 
and 1B). Staining for phospho-ERK was most intense 
in the nuclei and weaker in the cytoplasm of all 
immunopositive cells (Figure 1A and 1B). This concurs 
with the fact that most ERK is rapidly imported into the 
nucleus following its phosphorylation [6, 7]. Controls 
(type-matched IgG1 as well as lambda phosphatase 
pre-treatment) were negative. Staining of stromal and/
or inflammatory cells was as strong in biopsies that 
contained positive cancer cells (Figure 1A) as in biopsies 
that contained weakly reactive or no positive cancer 
cells (Figure 1B). This internal control attested that the 
quality of tissue fixation and staining was optimal in all 
biopsies. Finally, staining for ERK protein (irrespective 
of phosphorylation status) showed that it was present also 
in cancer cells that showed no phospho-ERK staining. 
Accordingly, as previously noted for colorectal carcinomas 
[11], lack of ERK phosphorylation did not reflect lack of 
ERK protein expression.
Two observers, who were unaware of the clinical 
data and outcomes, scored all (coded) specimens 
independently. Cancer cell nuclei, as well as nuclei of 
intertwining stromal cells, were scored for phospho-ERK 
staining with respect to average intensity (on a scale 
from 0–3 with 0 representing no staining and 3 intense 
staining) and number (in 10% increments using a scale 
from 0–10). Multiplication of the intensity and number 
scores produced observed ranges of product scores from 
0–21.5 in cancer cell nuclei (Supplementary Figure 1) and 
of 1–27.0 in stromal cell nuclei (theoretical range: 0–30 
for both). There was excellent agreement between the 
two observers (kappa = 0.76) and results are presented 
as averages of their scores. The product score showed 
no significant correlation to baseline clinical data (age, 
gender, and, as assessed by MRI; tumor length, tumor 
location, distance from the mesorectal fascia, cN or cT). 
Initially, we validated the scores by determining 
whether we could reproduce the effects of our previous 
finding [10] that pre-treatment phospho-ERK scores 
could predict effects of RCT on downstaging and tumor 
regression grade (TRG) in this new cohort of patients.
Major downstaging was defined as cT-ypT>1, 
ypN=0 (all major downstagers were without nodal 
involvement). Patients with cancer phospho-ERK 
scores above the median (≥4.5) never achieved major 
downstaging (Figure 2A). Moreover, no patients with 
scores below 4.5 showed a ypT category above 2 
following RCT. Notably, however, whilst a score above 
the median predicted poor downstaging, a score below 
the median was no guarantee for major downstaging 
(Figure 2A). The median cancer cell phospho-ERK 
score was significantly lower (Mann-Whitney U -test 
p = 0.0068) for major downstagers (2.5; n = 11) than that 
for patients showing poor or no downstaging (6.0; n = 48). 
ROC analyses (Figure 3A) produced an area under curve 
(AUC) of 0.76 (p = 0.006). In contrast, phospho-ERK 
scores of stromal cell nuclei in the same tumor sections 
showed no predictive power (Figure 3B). 
Similarly, no patients with cancer cell scores above 
the median (4.5) achieved total tumor regression (TRG1; 
Figure 2B) and the median cancer cell phospho-ERK score 
was significantly (p = 0.02) lower for TRG1 responders 
(2.25) than for patients who responded moderately to 
poorly (TRG3-5; 6.0). All patients achieving TRG1 
were devoid of lymph node metastases in the resection 
specimens (pN=0) and, thus, represented complete 
pathological responses (cPRs). Whilst a high phospho-
ERK score was incompatible with TRG1/cPR, a low 
score did not necessarily indicate a good TRG response 
(Figure 2B). ROC analyses (Figure 3C) for separating 
total responders (TRG1) from poor responders (TRG3-5) 
showed an AUC of 0.82 (p = 0.009), whilst phospho-ERK 
scores of stromal cell nuclei in the same tumor section 
showed no predictive power (Figure 3D). These results 
pertained to all patients. We additionally analyzed the 
subset of patients who received 5FU alone. The results 
showed that the effects of pERK scores on downstaging 
and TRG could be reproduced in this subset of patients 
(Figure 3E and 3F). Patients receiving combined 
5FU+Oxaliplatin treatment were too few for statistical 
analyses but the same trend was observed (Figure 2A and 
2B shows color-coded dots for both treatments). These 
data show that our previously reported results [10] could 
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be reproduced with a high degree of fidelity in a second 
patient cohort.
We next examined whether the cancer or stromal 
nuclear phospho-ERK scores had any impact on RFS. It 
emerged that patients with cancer phospho-ERK levels 
above the median (≥4.5) had significantly shorter RFS 
than patients with phospho-ERK levels below the median 
(5-year-RFS: 56.3% versus 92.0%, p = 0.007) (Figure 4A). 
When used as a continuous variable, the cancer pERK 
score emerged as a borderline significant predictor for 
RFS (p = 0.07). In contrast, stromal phospho-ERK scores 
were not predictive for RFS, whether used as a continuous 
variable (p = 0.69; HR: 0.98, 95% CI 0.89–1.10) or 
dichotomized by the median (p = 0.7).
Further analyses revealed that the predictive value 
of the cancer cell phospho-ERK scores mainly reflected an 
impact on high-risk patients. The impact of phospho-ERK 
levels on RFS in patients with UICC stage II or III was 
significant at the p = 0.01 level (Figure 4B). Note that the 
median score for cancer cell phospho-ERK (6.0) in stage 
II-III patients was higher than the population median (4.5). 
It was noteworthy that UICC stage III patients, who had 
Figure 1: Phospho-ERK staining of tumors that show strong (A) or no (B) staining of cancer cells (exemplified with white asterisks). Note 
that stromal cells (arrowheads) are strongly stained in both A and B.
Figure 2: Scatter plots showing downstaging (A) and TRG scores (B) in relation to cancer cell phospho-ERK scores for all 59 patients of 
cohort 1. Data for patients treated with 5FU alone are shown as blue dots and for 5FU+oxaliplatin as red dots. Note that none of the patients 
with cancer cell phospho-ERK levels above the median score (4.5) respond with either major downstaging or complete tumor regression 
(TRG1 in A). The difference in cancer cell phospho-ERK scores between major and minor downstaging is significant both for all patients 
(p = 0.007) as well as for the 5FU+oxaliplatin group (p = 0.02). It is borderline significant (p = 0.06) for the group receiving 5FU alone. 
Note in B that the cancer cell phospho-ERK score is lower in patients experiencing higher degrees of tumor regression (1 = total; 5 = none). 
The difference in median cancer cell phospho-ERK scores between the TRG1 and TRG3-5 group is significant for all patients (p < 0.02) as 
well as for the 5FU group alone (p = 0.03), whereas the 5FU+oxaliplatin group only contained a single case of complete tumor regression.
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Figure 3: ROC diagrams showing the predictive power of phospho-ERK scores in cancer cells (A, C, E, F) but not in intertwining stromal 
cells (B, D) for predicting major downstaging (A, B, E) and TRG1 (C, D, E, F) in all patients (A–D) as well as the subgroup of patients 
treated with 5FU alone (E, F). The black dotted line in each diagram illustrates an imaginary line of no predictive power (AUC = 0.5).
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low phospho-ERK scores, showed an RFS that was not 
significantly different from that of stage I-II patients (with 
low phospho-ERK scores) whilst stage III patients with 
high phospho-ERK scores showed very poor RFS (Figure 
4C). These differences were evident also when only T 
categories were analysed (Figure 4D).
Since patients with poor prognostic indicators 
frequently are offered postoperative (adjuvant) 
chemotherapy, we examined whether these results could 
be explained by effects of phospho-ERK levels on the 
outcome of such therapy. Indeed, the positive prognostic 
impact of low cancer cell phospho-ERK levels mainly, 
if not exclusively, reflected effects in the subset of 
patients who received adjuvant therapy (5-year-RFS: 
high score: 21.4% versus low score: 85.7%, p = 0.009) 
(Figure 5A). This group consisted of 14 patients (Table 
1), including 12 UICC stage III, 2 UICC stage II with a 
CRM distance <1 mm and one UICC stage I with non-
radical surgery. There were no differences in adjuvant 
treatment between patients having tumors showing high 
and low pERK scores: 5 in each group had received 
combined 5FU+oxaliplatin whilst the remaining two in 
each group had received 5FU alone. The phospho-ERK 
scores of stromal cells showed no predictive power 
(5-year-RFS: high score: 60%; low score: 50%; p = 0.7) 
(Figure 5B). The cancer phospho-ERK score also emerged 
as significant when used as a continuous variable (HR: 
1.32; 95% CI: 1.04–1.67; p = 0.025). Of other variables 
considered to be important to postoperative disease 
progression (ypN, ypT, UICC stage, critical CRM distance, 
Figure 4: Kaplan-Meier plots showing (A) recurrence free survival of all patients dichotomized by the median cancer cell phospho-ERK 
score (4.5). Note that patients with a score above the median show poorer RFS. (B) RFS for patients with UICC grade ≥ II in relation to the 
median cancer cell phospho-ERK score. Note that the median (6.0) is higher for these patients than for the entire patient group. Also note 
that patients with lower cancer cell phospho-ERK scores show significantly better (p = 0.01) RFS than patients with higher scores. (C) RFS 
for all 59 patients subdivided by the median cancer cell phospho-ERK score as well as by UICC grade 3. Note that patients with low cancer 
cell phospho-ERK scores show equally good survival, irrespective of the TNM grade, whereas patients with high cancer cell phospho-ERK 
scores and high grade show dismal RFS. (D) RFS in relation to T classification (ypT) and the median cancer cell phospho-ERK score for 
all patients. Note that patients with a ypT of 2 or more show almost as good RFS as ypT0-1 patients provided they have a low cancer cell 
phospho-ERK score, whereas such patients with a high score show much poorer RFS. Also note that, in keeping with the effects of the 
cancer cell phospho-ERK score on downstaging, there are no patients with a high cancer cell phospho-ERK score and a ypT below 2.
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tumor location, perineural and intravascular growth), only 
CRM (at <1 mm) was borderline significant (HR: 0.22; 
95% CI: 0.22–1.11; p = 0.07). In multivariate analysis, 
the (continuous) pERK score remained significant (HR: 
1.38; 95% CI: 1.04–1.84; p = 0.027) whilst CRM<1 mm 
remained borderline (HR: 0.163; 95% CI: 0.025–1.049; 
p = 0.06) and none of the remaining variables emerged as 
significant. Microsatellite instability was detected in only 
one of 11 patients examined (by immunohistochemistry 
for mismatch repair proteins MSH2, MSH6, MLH1 
and PMS2, cf ref 11). It was there not included in the 
multivariate analysis but, following exclusion of the single 
MSI tumor from the data set, cancer cell phospho-ERK 
levels remained significant (HR: 1.305; 95% CI: 1.02–
1.67; p = 0.036). Table 1 illustrates the characteristics 
of the 14 patients. Apart from the differences in median 
pERK scores, the two groups are remarkably similar and, 
as can be seen from the Kaplan-Meyer curve (Figure 5A), 
only one patient with a low cancer phospho-ERK score 
experienced a (late) relapse. However, there was a small 
difference indicating that patients who responded better 
to RCT (with respect to TRG and downstaging) also 
responded better to adjuvant therapy to the preceding RCT 
(Table 1). This difference was not significant, probably 
reflecting that good RCT responders did not exist in the 
adjuvant-treated group (Figure 6).
Forty-two of 56 cohort 1 patients did not receive 
adjuvant therapy (adjuvant therapy data were lacking for 
3 of the 59 patients; Table 2). In the patients not receiving 
adjuvant treatment, the cancer phospho-ERK score did not 
emerge as a significant predictor for RFS (5-year-RFS: 
high score: 76.2%; low score: 88.9%; p = 0.23) although 
a weak trend in favour of low scores was noted (Figure 
5C). These results show that the positive effect of a low 
pERK score on RFS of all patients of cohort 1 mainly 
reflected effects on the 14 patients, who did receive 
adjuvant therapy. However, the 42 patients, who did not 
receive adjuvant therapy, represented, of course, low-risk 
patients. We therefore included cohort 2, encompassing 
17 patients having UICC stage III and/or a CRM distance 
below 1 mm, which, according to DCCG criteria, were 
candidates for adjuvant therapy. These patients had not 
received any adjuvant treatment because of previous 
drug toxicity and/or comorbidities that had resulted in 
reductions or discontinuation of their neoadjuvant RCT 
(which is why they had not been included in cohort 1 for 
studying downstaging and TRG). In this “control” group, 
the pERK score, as dichotomized by the median, showed 
no significant predictive power (5-year-RFS: high score: 
62.5%; low score: 55.6%; p = 0.50) (Figure 5D).
DISCUSSION
The most important new finding of our study is 
that the cancer, but not stromal, phospho-ERK score, as 
determined on diagnostic biopsies, constitutes a significant 
predictor for RFS of LARC patients. We were able to 
demonstrate that this effect mainly, if not exclusively, 
reflected effects of the response to adjuvant CT 
administered to high-risk patients following surgery. Thus, 
although our data fully confirms that the same phospho-
ERK scores predict the response to preoperative RCT [10], 
the present data extends these findings by showing effects 
on the outcome of adjuvant therapy. There were only a 
small difference between the RCT response in terms of 
either TRG or downstaging and the subsequent response to 
adjuvant therapy. This may reflect the fact that all patients 
who received adjuvant therapy were (almost by definition) 
Table 1: Characteristics of the 14 patients of cohort 1, who received adjuvant therapy, subdivided 
according to relapses
Variable No recurrences (n = 8) Recurrences (n = 6)1
age 67.5 (48–76) years 66.5 (55–69) years
gender (female: male ratio) 3:5 0:6
cancer cell phospho-ERK score 2.3 (0–10.5) 8.6 (0.5–12.5)
stromal cell phospho-ERK score 10.0 (1.5–27.0) 10.3 (5.0–14.8)
TRG 2.5 (2–3)2 3.0 (2–5)3
downstaging (cT-ypT) 0 (0–1) 0 (–14–1)
pT 3 (2–3) 3 (2–4)
pN 1 (0–2) 1 (0–2)
deaths (ratio) 0:8 2:6
If not otherwise indicated, numbers refer to medians with total ranges given in brackets.
1 3 patients had liver metastases, 2 had lung metastases and one had disseminated disease.
2 4 TRG2 and 4TRG3.
3 2 TRG2, 3TRG3, 1 TRG5.
4 one patient upstaged during RCT.
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minor (cT-ypT≤1) downstagers and showed incomplete 
TRG responses (Table 1). However, as indicated in Table 
1, there was a trend suggesting that a better, albeit small, 
response to RCT correlated to a better response to adjuvant 
therapy. It is worthy of note that whilst a high cancer (but 
not stromal) phospho-ERK score never was associated 
with major downstaging or total tumor regression, the 
reverse was not true. Thus, a low cancer phospho-ERK 
score did not serve to exclude a poor response with respect 
to these outcomes. However, most of these patients showed 
best response to subsequent adjuvant therapy (as illustrated 
by color-coding in Figure 6).
Our results are consonant with previous studies 
showing that high levels of phospho-ERK interferes with 
effects of 5FU as well as of radiation on cancer cells in 
vitro [13–15]. Together, the results support the idea that 
high phospho-ERK levels render rectal cancer cells 
insensitive to CT. This could be due to multiple factors. 
Firstly, both chemotherapy and radiation work by inducing 
apoptosis and phospho-ERK constitutes an important 
regulator of this event [6, 7]. Additionally, phospho-
ERK stimulates expression of the anti-apoptotic protein 
survivin [16, 17] which correlates with survival of RCT-
treated colorectal cancers [18]. This further underlines 
the importance of cancer cell phospho-ERK levels for 
responses to RCT. A low cancer phospho-ERK score was 
not invariably associated with a good RCT response but 
was, as pointed out above, statistically associated with a 
better RFS in patients receiving adjuvant therapy. This 
is most likely due to additional factors, which determine 
the sensitivity of tumor cells to 5FU. Such factors include 
drug transporters, microRNA expression patterns and 
several others. Accordingly, we posit that the impact 
of low phospho-ERK levels may be cancelled by such 
factors, whilst the apoptosis-preventing effect of high 
phospho-ERK levels is dominant.
Separate analysis of the 42 patients of cohort 1, who 
did not receive adjuvant therapy, showed no significant effect 
Figure 5: Kaplan-Meier plots showing (A) RFS for the 14 patients of cohort1, who received adjuvant treatment, dichotomized by the 
median cancer cell phospho-ERK score (6.0) (B) RFS for the 14 patients of cohort 1, dichotomized by the median stromal cell phospho-
ERK score. (C) RFS for the 42 remaining patients of cohort 1, who did not receive adjuvant treatment (3 further patients of cohort1 lacked 
data regarding adjuvant treatment) dichotomized as in A. (D) RFS for the 17 patients of cohort 2, who fulfilled the criteria, but who did not 
receive, adjuvant treatment, dichotomized by the median cancer cell phospho-ERK score.
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Table 2: Characteristics (median and ranges, where relevant) for patients receiving full preoperative 
radiochemotherapy (RCT)
Full RCT
n (gender) 59 (15 f, 44 m)
age 67 (43–84)
full image-gudied RT 59
RCT with 5FU 48
RCT with 5FU+oxaliplatin 11
postop chemotherapy 14 (n = 56)
cT2 2 (n = 59)
cT3 45 (n = 59)
cT4 12 (n = 59)
cN0 12 (n = 47)
cN1 18 (n = 47)
cN2 17 (n = 47)
tumor length (cm) 6 (2–10; n = 21)
mesorectal fascia distance (mm) 1.5 (0–15; n = 26)
low/medium-high tumors 16/22 (n = 38)
MRI was used for recording clinical tumor (cT) and lymph node classification (cN), median tumor length, median distance 
from the mesorectal fascia (when applicable) and tumor location. Numbers given in parentheses indicate number of records 
available for each variable.
Figure 6: Scattergram summarizing cancer cell phospho-ERK scores for all individuals of cohort 1. Patients receiving 
adjuvant treatment without subsequent recurrences are indicated with green dots and patients receiving adjuvant treatment with subsequent 
recurrences are indicated with red dots. Patients not receiving adjuvant treatment are shown in grey. Note that the majority of patients not 
experiencing recurrences had phospho-ERK scores below the median.
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of cancer phospho-ERK scores on RFS. Thus, although we 
observed that phospho-ERK scores predicted significantly 
better RFS for the patients of cohort 1 (and could predict 
much better RFS for the high-risk patient subgroup) this 
mainly reflected effects on the group of the 14 patients 
who did receive adjuvant treatment. To determine whether 
this was an effect relating directly to interference of high 
phospho-ERK with CT we therefore studied an additional 
group of 17 patients, who were eligible to, but who did not 
receive, adjuvant therapy (due to previously experienced 
drug toxicity or comorbidities). These patients did not show 
any significant effect of cancer phospho-ERK levels on RFS. 
We take this as a strong indication that the phospho-ERK 
score predominately predicts the CT response. However, it 
is highly likely that phospho-ERK also affects many other 
aspects of cancer cell growth, survival and motility and, 
indeed, in the 42 non-adjuvant receiving patients, a non-
significant trend towards better RFS for low cancer phospho-
ERK scores was observed.
It is of considerable interest that the phospho-ERK 
scores could be used to stratify high-risk patients (like 
UICC stage III) into a poor and a good prognostic group. 
Although, again, this mainly (or exclusively) reflected 
effects on adjuvant therapy it is remarkable that levels 
determined in diagnostic, pre-treatment biopsies have 
so strong an impact subsequent to both neoadjuvant 
and adjuvant treatment. It is a limitation of the present 
study that the number of patients receiving postoperative 
adjuvant treatment is relatively small. Nevertheless, the 
difference in RFS between the high and low phospho-ERK 
group is very marked and highly significant. A follow-up 
study addressing a larger patient material is currently 
being planned. If these findings can be confirmed in an 
independent material it opens for use of phospho-ERK as 
a new predictive marker that perhaps may be useful also 
in other cancer forms, like colonic carcinoma. It also poses 
the question whether MEK inhibitors, which increase the 
efficiency of 5FU in cultured cells [15], could be useful 
supplements to neoadjuvant/adjuvant therapy of rectal 
carcinoma patients. Such inhibitors are now in clinical use 
and do also target oncogenic MEK mutations in colorectal 
cancers, which may occur secondarily to BRAF inhibitor 
treatment [21].
MATERIALS AND METHODS
Ethics statement
The study was approved by the Danish Data 
Protection Agency (AHH-2016-044: I-Suite 04853) and 
Ethical Committee (protocol H-15015151). 
Patients
Fifty-nine patients, consecutively diagnosed with 
LARC at three major Copenhagen hospitals (Herlev, 
Hilleroed and Gentofte) during 2008–2015, received full 
concomitant neoadjuvant RCT, including image-guided 
RT and had no distant metastases at the time of diagnosis 
and no coexisting malignancies (cohort 1). This patient 
cohort did not encompass any of the patients reported in 
our previous study [10]. Patient details are summarized 
in Table 2. The majority of these patients (n = 48) 
received peroral 5-fluorouracil (5FU) alone whilst 11 
patients received 5FU in combination with oxaliplatin. 
Subsequently, 14 patients received postoperative 
(adjuvant) chemotherapy (CT) (Table 1). Ten of these 
patients received adjuvant therapy with 5FU combined 
with oxaliplatin, whereas 4 patients received 5FU alone. 
Tumor location was noted as low (starting 0–5 cm above 
the anal verge), medium (5–10 cm) and high (10–15 cm). 
Tumor length, distance from the mesorectal fascia, clinical 
tumor (cT) and node (cN) classifications were determined 
by magnetic resonance imaging (MRI). Tumor length was 
used for indicating tumor size.
We additionally analysed data from 17 patients 
(cohort 2), who also had been diagnosed with LARC 
during the same time-span at the same hospitals as 
cohort 1. However, these patients were not included in 
cohort 1, because they had not received full neoadjuvant 
CT treatment (due to drug toxicity or comorbidities). 
Postoperatively, these patients fulfilled the Danish 
colorectal cancer group (DCCG) criteria for adjuvant 
(UICC stage III and/or a CRM distance below 1 mm) 
therapy but they did not receive such therapy because 
of the above concerns regarding toxicity and/or 
comorbidities. Specimens from both cohort 1 and 2 were 
simultaneously stained, blind coded and scored in the 
same run (as detailed in the subsequent sections).
Tissue analyses
Endoscopic biopsies were immediately fixed in 
10% buffered neutral formalin and embedded in paraffin. 
Adjacent 3-μm sections were stained with HE and for 
immunohistochemistry. The latter involved demasking 
of sections at high pH and staining with two previously 
well-characterized [10, 11] mouse monoclonal antibodies, 
specifically detecting phosphorylation of Thr202/Tyr204 
in ERK1 and of Thr185/Tyr187 in ERK2(clone Milan8R; 
mouse IgG1, eBioscience/Affymetrix, San Diego, CA), or 
detecting ERK1/2 protein regardless of its phosphorylation 
status (clone L34F12; mouse IgG1, #4696, Cell Signaling 
Technology, Leiden, Netherlands), using automated 
staining machines and immunoperoxidase detection as 
described [10–12]. Controls included substitution of the 
monoclonal antibodies with type-matched control mouse 
IgG1 as well as dephosphorylation prior to phospho-ERK 
staining, as described [10, 11]. Validation of the phospho-
ERK antibody included, besides the controls outlined 
above, full length Western blotting, which revealed only 
the expected 42- (phospho-ERK2) and 44-kDa (phospho-
Oncotarget1754www.oncotarget.com
ERK1) bands [11]. Sections from surgical resection 
specimens were stained with HE for determining TRG, 
using the Mandard scale [19, 20] from 1 (total regression) 
to 5 (no regression). This scale was routinely used in the 
hospitals involved.
Scoring and statistics
Two observers independently scored all sections 
stained for phospho-ERK from all patients (cohort 
1+2) in the same run using blind-coded specimens. The 
average staining intensities of cancer cell nuclei in each 
section were graded as absent (0), weak (1), moderate 
(2) or strong (3) and percentages of stained cancer cell 
nuclei were scored as 0 (0), 1–10 (1), 11–20 (2), etc. in 
10%-increments. RFS, in days counted from the day of 
primary surgery, were analysed. All relapses involved 
metastatic disease. Downstaging was defined as the 
difference (cT-ypT) between T categories, as determined 
by MRI (cT) before RCT and by pathology (ypT) 
following RCT and surgery. Statistics used SAS (version 
9.4, SAS Institute, Cary, NC). Survival curves were 
constructed with the Kaplan-Meier method and equality 
over strata evaluated with log-rank statistics. The Cox 
proportional hazard model was used for multivariate 
analysis and included estimates of the hazard ratio (HR) 
with 95% Wald confidence limits. Multivariate analysis 
included stepwise elimination of variables. Differences in 
TRG and downstaging in relation to phospho-ERK scores 
were analysed by receiver operating curves (ROCs) as 
described [10]. The significance level was set at 5%.
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